cp-70429 has been researched along with fropenem* in 1 studies
1 other study(ies) available for cp-70429 and fropenem
| Article | Year |
|---|---|
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in
The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Escherichia coli; Meropenem; Microbial Sensitivity Tests | 2023 |